NCM USA

NCM USA NCM’s strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribut

https://www.sciencedaily.com/releases/2017/02/170201110542.htm
02/02/2017

https://www.sciencedaily.com/releases/2017/02/170201110542.htm

Researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent -- a PET radiotracer -- is both safe and effective.

https://www.eurekalert.org/pub_releases/2017-01/sonm-nta010517.php
01/06/2017

https://www.eurekalert.org/pub_releases/2017-01/sonm-nta010517.php

A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer. The study is published in the January 2017 i...

01/08/2013

Since '99 N-13 Ammonia has been on FDA's radar, now NCM-USA is making this vital drug available for select clinics in the NYC area.

This is a primary medical and statistical review of N-13 ammonia radiopharmaceutical used in positron emission tomography (PET) for the indication of assessing myocardial blood perfusion in the evaluation of coronary artery disease (CAD), following separate administration under rest and stress condi...

Address

New York, NY

Alerts

Be the first to know and let us send you an email when NCM USA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram